References
Abdallah Y, Gligorievski D, Kasseckert SA, Dieterich L, Schafer M, Kuhlmann CR, et al. (2007). The role of poly(ADP-ribose) polymerase (PARP) in the autonomous proliferative response of endothelial cells to hypoxia. Cardiovasc Res 73: 568-574.
Altmeyer M, Barthel M, Eberhard M, Rehrauer H, Hardt WD, & Hottiger MO (2010). Absence of poly(ADP-ribose) polymerase 1 delays the onset of Salmonella enterica serovar Typhimurium-induced gut inflammation. Infect Immun 78: 3420-3431.
Atasheva S, Akhrymuk M, Frolova EI, & Frolov I (2012). New PARP gene with an anti-alphavirus function. J Virol 86: 8147-8160.
Atasheva S, Frolova EI, & Frolov I (2014). Interferon-stimulated poly(ADP-Ribose) polymerases are potent inhibitors of cellular translation and virus replication. J Virol 88: 2116-2130.
Ba X, & Garg NJ (2011). Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases. Am J Pathol 178: 946-955.
Beneke S, & Burkle A (2007). Poly(ADP-ribosyl)ation in mammalian ageing. Nucleic Acids Res 35: 7456-7465.
Benko R, Pacher P, Vaslin A, Kollai M, & Szabo C (2004). Restoration of the endothelial function in the aortic rings of apolipoprotein E deficient mice by pharmacological inhibition of the nuclear enzyme poly(ADP-ribose) polymerase. Life Sci 75: 1255-1261.
Black JH, Casey PJ, Albadawi H, Cambria RP, & Watkins MT (2006). Poly adenosine diphosphate-ribose polymerase inhibitor PJ34 abolishes systemic proinflammatory responses to thoracic aortic ischemia and reperfusion. J Am Coll Surg 203: 44-53.
Boulares AH, Zoltoski AJ, Sherif ZA, Jolly P, Massaro D, & Smulson ME (2003). Gene knockout or pharmacological inhibition of poly(ADP-ribose) polymerase-1 prevents lung inflammation in a murine model of asthma. Am J Respir Cell Mol Biol 28: 322-329.
Channappanavar R, & Perlman S (2017). Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 39: 529-539.
Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. (2020). Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368: m1091.
Cheng P, Zhu H, Witteles RM, Wu JC, Quertermous T, Wu SM, et al.(2020). Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty. Curr Cardiol Rep 22: 34.
Coultas DB, Zumwalt RE, Black WC, & Sobonya RE (1994). The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 150:967-972.
Curtin N, Banyai K, Thaventhiran J, Le Quesne J, Helyes Z, & Bai P (2020). Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome? Br J Pharmacol.